Ranbaxy Makes "Practical" Bid For Merck KGaA's Generics Unit
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy confirmed reports that it made a bid for Merck KGaA's generic drugs unit, but the Indian generics company maintained that the offer does not overvalue the Merck asset
You may also be interested in...
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).